Molecular Subtypes Associated with Clinical Benefit in Cisplatin-Treated Metastatic Urothelial Cancer Patients
International Urology Cancer Summit shared on LinkedIn:
“Latest work published in Journal of Precision Oncology titled ‘Molecular Subtypes Are Associated with Clinical Benefit in Cisplatin-Treated Metastatic Urothelial Cancer Patients’.
In this study, Karin Holmsten et al. explored the impact of different molecular subtypes (based on the Lund Taxonomy) on treatment response and survival outcomes in patients with metastatic urothelial cancer (mUC) receiving first-line cisplatin-based chemotherapy.
Key findings:
– Patients with mesenchymal-like (Mes-like) subtypes showed significantly lower response rates and shorter survival.
– Luminal subtypes (urothelial-like and genomically unstable) had the best response and longest survival.
This research provides critical insights that could help guide future treatment decisions, particularly in developing precision medicine strategies for mUC.
Check it out here.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023